Evaluation Reports Archive

The following Evaluation reports have been archived and are no longer available as downloads from this website. If you would like to have access to any of the documents listed please contact nuth.nyrdtc.rxsupp@nhs.net.

<< Return to the list of current Evaluation Reports

Document Published
Abiraterone for the treatment of castration-resistant prostate cancer Feb 11
ActiPatch Jan 19
Adacolumn in Inflammatory Bowel Disease (NETAG appraisal) Jan 11
Adefovir dipivoxil in chronic hepatitis B infection (N) Jun 04
Aflibercept for age-related macular degeneration (NETAG Appraisal) Mar 12
Alemtuzumab in chronic lymphocytic leukaemia Mar 07
An update on newer agents for the treatment of pulmonary hypertension Mar 04
Aprepitant for the prevention of chemotherapy induced nausea and vomiting Mar 09
Aromatase inhibitors in early stage breast cancer (N) Mar 07
Azacitidine for the management of myelodysplastic syndromes (N) May 09
Belimumab for the treatment of Systemic Lupus Erythematosus (SLE) Apr 12
Bendamustine for rituximab-refractory non-hodgkin’s lymphoma Feb 11
Bevacizumab in metastatic breast cancer (N) Sep 07
Birch bark extract (Episalvan) for the treatment of partial thickness wounds in adults Sep 16
Bortezomib second-line in multiple myeloma (N) Mar 06
Botox for chronic migraine (NETAG appraisal) Sep 11
Cabazitaxel for the treatment of metastatic hormone-refractory prostate cancer Feb 11
Dasatinib in the management of acute lymphoblastic leukaemia in adults Aug 08
Docetaxel or paclitaxel in early stage breast cancer (N) Mar 06
Doxylamine and pyridoxine (Xonvea®) for the treatment of nausea and
vomiting of pregnancy
Feb 19
Drotrecogin alfa (activated) in severe sepsis (N) Dec 02
Eculizumab in atypical Haemolytic Uraemic Syndrome Jul 12
Entecavir in chronic hepatitis B (N) Apr 07
Erlotinib in non-small cell lung cancer Mar 06
Fampridine  for the improvement of walking ability in multiple sclerosis Sep 11
Fulvestrant Jan 18
Human Immunodeficiency Virus (HIV) infection - new treatments May 10
Ibandronic acid in hypercalcaemia of malignancy, bone pain and the prevention of skeletal events associated with skeletal metastases Aug 05
Ibritumomab as consolidation therapy after remission induction in previously untreated follicular lymphoma May 09
Ibritumomab in b-cell follicular non-hodgkin’s lymphoma Mar 06
Insulin degludec in Diabetes mellitus Aug 12
Lapatinib in the management of metastatic breast cancer Nov 08
Myocet in the management of metastatic breast cancer Aug 08
Naloxone Nasal Spray Sep 18
Nanoparticle albumin-bound paclitaxel in the management of metastatic breast cancer May 10
Natalizumab in multiple sclerosis (N) Mar 07
Neuromodulatory drugs for cough Nov 17
Newer Topical Therapies for Actinic Keratoses Apr 13
Omalizumab in severe persistent allergic asthma (N) Jun 06
Ozurdex dexamethasone ocular implant for uveitis (NETAG appraisal) Jan 12
Palonosetron for the prevention of nausea and vomiting associated with cancer chemotherapy Mar 07
Panitumumab in the management of metastatic colorectal cancer (N) Jun 06
Pasireotide for Cushing’s disease (NETAG Appraisal) Jun 12
Pegvisomant in acromegaly Jan 06
Pemetrexed in malignant pleural mesothelioma (N) Mar 06
Perampanel for epilepsy (NETAG appraisal) Oct 12
Protease Inhibitors (Boceprevir & Telaprevir) in the treatment of Hepatitis C Dec 11
Pulmonary arterial hypertension - Current therapeutic strategies Mar 09
Rituximab in combination with cvp chemotherapy for the management of follicular non-hodgkin’s lymphoma Mar 06
Rituximab in rheumatoid arthritis: non-NICE approved indications (N)
Jul 11
Roflumilast for COPD (NETAG appraisal) (N) Jun 10
Ruxolitinib for myelofibrosis Jan 13
Sativex for spasticity due to MS (NETAG appraisal) Oct 10
Sorafenib for the treatment of locally advanced or metastatic medullary thyroid cancer Feb 11
Sufentanil Sublingual Tablet for Post-Operative Pain Mar 16
Sunitinib for the treatment of Pancreatic Neuroendocrine Tumours (PNETs) Mar 11
Tapentadol for chronic pain Jan 15
Targinact for chronic pain Jan 15
Teriparatide in osteoporosis (N) Jul 04
Tocilizumab for juvenile idiopathic arthritis (NETAG appraisal) (N) Jul 10
Tolvaptan for SIADH (NETAG appraisal) Apr 11
Topical gabapentin Nov 15
Tumour Necrosis Factor Inhibitors for Rheumatoid Arthritis May 13
Vandetanib in locally advanced or metastatic medullary thyroid cancer Feb 11